ClinicalTrials.gg
RecruitingNCT05064917Updated May 3, 2022

BAT Cow's Milk for the Replacement of the Food Challenge Test

An observational study in Cow Milk Allergy, sponsored by Rijnstate Hospital. Recruiting at 1 site in Netherlands. Open to participants aged Up to 12 Years. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Rijnstate Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
Up to 12 Years
Sex
All
01

Study summary

The prevalence of children suspected of a cow's milk allergy is 17% in the Netherlands. Cow's milk diagnosis is based on a food challenge test However, this food challenge test is expensive, time consuming, risky, with waiting lists of several months. This waiting time results in unnecessarily long-term use of expensive hypoallergenic milk formula Therefore, there is a great need to introduce a better and faster diagnostic test for cow's milk allergy diagnosis in standard care. The in vitro Basophil Activation Test (BAT) is cheap, quick (result \< 1 day, no waiting list), safe for the child and is a reliable alternative for the food challenge test to diagnose an IgE-mediated allergy. A diagnostic work-up with the BAT is expected to achieve a relevant reduction in the number of expensive and risky food challenges and the prescription of hypoallergenic formula. The reduction in diagnostic delay will increase quality of life.

Objective: Determination of the (cost)effectiveness of the replacement of the expensive, risky and time-consuming food challenge test by the Basophil Activation Test (BAT) for the diagnosis of an IgE-mediated cow's milk allergy in children.

02

Conditions studied

  • Cow Milk Allergy

Browse trials for

Keywords

  • Basophil Activation test
  • Cow's milk
  • oral food challenge
03

In context

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

This study's planned enrollment of 700 is above the median of 102 across 45 observational studies indexed under Milk Hypersensitivity.

Browse Milk Hypersensitivity studies →

Lead sponsor

Rijnstate Hospital is the lead sponsor of 130 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children suspected of an IgE-mediated cow's milk allergy and are eligible for a food challenge test at 2nd and 3rd line allergy centres.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 0-12 years
  2. Suspected of cow's milk allergy with one or more of the following complaints after intake of cow's milk:

    • angioedema
    • urticaria
    • sneezing and rhinitis \<2 hours after feeding
    • sensation of swelling in the throat and/or difficulty swallowing \<2 hours after feeding
    • voice change/hoarseness \<2 hours after feeding
    • cough \<2 hours after feeding
    • wheezing and/or shortness of breath \<2 hours after feeding
    • loss of consciousness \<2 hours after feeding
    • vomiting or abdominal pain or diarrhoea \<2 hours after feeding in children \<4 years only in combination with IgE-mediated complaints in other tracts
  3. Placed on a waiting list for a hospital food challenge test
  4. Blood draw for cow's milk sIgE and BAT \< 3 months before the food challenge test. This blood draw will be simultaneously scheduled with a blood draw for regular diagnostics.
  5. Signed parents/guardians

Exclusion criteria

Exclusion Criteria:

  1. Age > 12 years
  2. Suspicion of Food Protein-Induced Enterocolitis Syndrome (FPIES)
  3. Eosinophilic esophagitis due to a cow's milk allergy
  4. Suspected cow's milk allergy \<4 years with crying and/or agitation and/or eczema and/or abdominal pain and/or failure to thrive and/or blood loss per anum and/or diarrhoea and/or reflux and/or vomiting as the only manifestation of the allergy without IgE-mediated symptoms in another organ system
  5. Systemic use
  6. Other underlying chronic conditions (immunological, oncological, chromosomal abnormalities).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with suspected cow's milk allergy

    Diagnostic Test: Blood draw

Interventions

  • Diagnostic testBlood draw

    The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of the in vitro Basophil Activation Test (BAT) Cow's Milk

    Time frame: 3 months

Secondary outcomes

  1. Cost-effectiveness of the BAT cow's milk

    Cost-effectiveness of the BAT cow's milk compared to the food challenge test

    Time frame: 1 year

  2. Food allergy Quality of life

    Quality of life measured by The Food Allergy Quality of Life Questionnaire (FAQLQ-CF)

    Time frame: Before and one month after the food challenge test

  3. Health related Quality of life

    Quality of life measured by Kidscreen-10

    Time frame: Before and one month after the food challenge test

07

Study locations

1 of 1 sites recruiting
  • Janneke Ruinemans
    Arnhem, Gelderland 6815 AD, Netherlands
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Dec 2025, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2021
First posted
Oct 1, 2021
StartActual
Nov 1, 2021
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05064917
Lead sponsor
Rijnstate Hospital
Collaborators
Alrijne Hospital, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Bernhoven Hospital, Catharina Ziekenhuis Eindhoven, Elkerliek Hospital, Erasmus Medical Center, Elisabeth-TweeSteden Ziekenhuis, Maasstadziekenhuis, Meander Medisch Centrum, OLVG, Spaarne Gasthuis, Franciscus Gasthuis, University Medical Center Groningen, UMC Utrecht, Viecurie Medisch Centrum voor Noord LImburg, Zuyderland Medisch Centrum
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Nov 1, 2021
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
May 3, 2022

Study contacts

Janneke Ruinemans, Dr
Contact
JRuinemans-Koerts@rijnstate.nl
088-0058888
Joyce Emons, Dr
Contact
j.a.m.emons@erasmusmc.nl
010-7036263

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion